Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Fidelity Disruptive Medicine ETF (FMED)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: FMED (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 8.09% | Avg. Invested days 61 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Volume (30-day avg) - | Beta 0.83 | 52 Weeks Range 20.69 - 26.79 | Updated Date 06/30/2025 |
52 Weeks Range 20.69 - 26.79 | Updated Date 06/30/2025 |
Upturn AI SWOT
Fidelity Disruptive Medicine ETF
ETF Overview
Overview
The Fidelity Disruptive Medicine ETF (FMED) seeks to provide investment results that correspond to the performance of companies involved in the disruptive medicine sector, focusing on areas like gene therapy, robotic surgery, and medical technology advancements. It offers exposure to innovative companies driving change in healthcare.
Reputation and Reliability
Fidelity is a well-established and reputable asset manager with a long history in the financial services industry.
Management Expertise
Fidelity has a dedicated team of investment professionals with experience in healthcare and technology sectors.
Investment Objective
Goal
To provide investment results that correspond to the performance of companies involved in disruptive medicine.
Investment Approach and Strategy
Strategy: The ETF does not track a specific index but uses a bottom-up fundamental approach to select companies involved in disruptive medicine.
Composition Primarily holds stocks of companies in the healthcare and technology sectors, with a focus on those involved in innovative medical technologies and therapies.
Market Position
Market Share: Data not available to calculate specific market share.
Total Net Assets (AUM): 107500000
Competitors
Key Competitors
- ARKG
- XBI
- PJP
Competitive Landscape
The disruptive medicine ETF landscape is competitive, with ARKG and XBI holding significant market share. FMED benefits from Fidelity's resources but faces challenges in gaining traction against established players. ARKG offers a more concentrated approach, while XBI provides broader exposure to the biotech industry. FMED seeks a middle ground, emphasizing disruptive technologies specifically.
Financial Performance
Historical Performance: Historical performance data is not available in provided data.
Benchmark Comparison: Benchmark comparison data is not available in provided data.
Expense Ratio: 0.39
Liquidity
Average Trading Volume
The ETF's average trading volume suggests moderate liquidity, facilitating relatively easy entry and exit for investors.
Bid-Ask Spread
The bid-ask spread is typically tight, indicating efficient trading and lower transaction costs.
Market Dynamics
Market Environment Factors
Economic indicators, healthcare spending trends, regulatory changes, and technological advancements in medicine impact the ETF's performance.
Growth Trajectory
The ETF's growth depends on the adoption of disruptive medical technologies, investment in healthcare innovation, and the regulatory environment for new therapies.
Moat and Competitive Advantages
Competitive Edge
FMED benefits from Fidelity's brand recognition and distribution network. The ETF's focus on disruptive medicine provides a targeted approach for investors seeking exposure to innovative healthcare technologies. Fidelity's expertise in both healthcare and technology sectors potentially allows for informed investment decisions. This focused approach aims to capture growth opportunities within the disruptive medicine space.
Risk Analysis
Volatility
Volatility is expected to be moderate to high, reflecting the growth-oriented nature of the disruptive medicine sector.
Market Risk
Market risk includes potential regulatory hurdles, clinical trial failures, and competition from established pharmaceutical companies.
Investor Profile
Ideal Investor Profile
The ideal investor is one with a high-risk tolerance, a long-term investment horizon, and an interest in the healthcare and technology sectors.
Market Risk
This ETF is suitable for long-term investors seeking growth potential through exposure to disruptive medical technologies and are willing to accept higher volatility.
Summary
Fidelity Disruptive Medicine ETF (FMED) offers targeted exposure to companies revolutionizing the healthcare industry. Backed by Fidelity's resources, it invests in innovative medical technologies. Its success hinges on the adoption of these technologies. The ETF is best suited for long-term investors with a high-risk tolerance looking for growth potential in disruptive medicine. The fund faces strong competition but benefits from Fidelity's brand and expertise.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fidelity Investments Website
- ETF.com
- Morningstar
Disclaimers:
Data and analysis are for informational purposes only and do not constitute investment advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fidelity Disruptive Medicine ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.